loratadine has been researched along with Rhinitis, Allergic, Perennial in 98 studies
Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.
loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.
Rhinitis, Allergic, Perennial: Inflammation of the mucous membrane of the nose similar to that found in hay fever except that symptoms persist throughout the year. The causes are usually air-borne allergens, particularly dusts, feathers, molds, animal fur, etc.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Desloratadine-montelukast combination therapy causes subjective and objective decrease in nasal obstruction, reduces the other symptoms of PAR and improves the disease-specific QoL." | 9.17 | Desloratadine-montelukast combination improves quality of life and decreases nasal obstruction in patients with perennial allergic rhinitis. ( Cingi, C; Erdogmus, N; Eskiizmir, G; Oghan, F; Ural, A; Yaz, A, 2013) |
| "Bilastine is an orally administered, second-generation antihistamine used in the symptomatic treatment of seasonal or perennial allergic rhinoconjunctivitis and urticaria." | 8.88 | Bilastine: in allergic rhinitis and urticaria. ( Carter, NJ, 2012) |
| "Nasal obstruction is the main symptom in patients with perennial allergic rhinitis." | 6.71 | Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. ( Allen, M; Barberi, S; Ciprandi, G; Cirillo, I; Civardi, E; Marseglia, GL; Vizzaccaro, A, 2005) |
| "Sinusitis was diagnosed by symptoms and confirmed by rhinoscopy and sinus radiograph." | 6.68 | Adjunct effect of loratadine in the treatment of acute sinusitis in patients with allergic rhinitis. ( Alabert, JP; Bousquet, J; Braun, JJ; Cougnard, J; Czarlewski, W; Michel, FB; Quiniou, M; Rat, C, 1997) |
| " Desloratadine is highly selective for histamine H₁-receptors, does not cross the blood-brain barrier (BBB), and has minimal adverse events (very low sedation rate), with a better safety and tolerability than first-generation antihistamines." | 6.49 | Safety evaluation of desloratadine in allergic rhinitis. ( González-Núñez, V; Mullol, J; Valero, A, 2013) |
| "Desloratadine is a once-daily, non-sedating, non-impairing, selective histamine H1-receptor antagonist." | 6.43 | Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. ( DuBuske, LM, 2005) |
| "Desloratadine-montelukast combination therapy causes subjective and objective decrease in nasal obstruction, reduces the other symptoms of PAR and improves the disease-specific QoL." | 5.17 | Desloratadine-montelukast combination improves quality of life and decreases nasal obstruction in patients with perennial allergic rhinitis. ( Cingi, C; Erdogmus, N; Eskiizmir, G; Oghan, F; Ural, A; Yaz, A, 2013) |
| "Nonsedating antihistamines (nsAHs) are recommended as first-line therapeutics for the treatment of mast cell-driven disorders, including allergic rhinitis and urticaria." | 5.14 | Suppression of histamine- and allergen-induced skin reactions: comparison of first- and second-generation antihistamines. ( dos Santos, RV; Lima, HC; Magerl, M; Mlynek, A, 2009) |
| "On the basis of low dose inhaled corticosteroid, orally administered Loratadine significantly improves the therapeutic efficacy of asthma in patients with allergic asthma and rhinitis." | 5.10 | [Effects of H1 blocker and inhaled corticosteroids on asthmatic patients with allergic rhinitis]. ( Cai, DM; He, WQ; Lin, H; Liu, HZ; Ran, PX; Xu, JM; Zheng, JP; Zhong, NS, 2003) |
| "Bilastine is an orally administered, second-generation antihistamine used in the symptomatic treatment of seasonal or perennial allergic rhinoconjunctivitis and urticaria." | 4.88 | Bilastine: in allergic rhinitis and urticaria. ( Carter, NJ, 2012) |
| "Levocetirizine and desloratadine are newer antihistamines indicated for the treatment of allergic rhinitis and chronic idiopathic urticaria." | 4.82 | A review of the evidence from comparative studies of levocetirizine and desloratadine for the symptoms of allergic rhinitis. ( Canonica, GW; Passalacqua, G, 2005) |
| "The second-generation H1-receptor antagonists terfenadine, astemizole, loratadine, and cetirizine are important first-line drugs for the relief of symptoms in patients with allergic rhinoconjunctivitis or chronic urticaria and may eventually supplant the potentially sedating first-generation H1-receptor antagonists in the treatment of these disorders." | 4.78 | Recent advances in H1-receptor antagonist treatment. ( Simons, FE, 1990) |
| " Desloratadine, a descarboethoxy derivative of loratadine, is a second generation antihistaminic drug approved for usage in allergic rhinitis among paediatric population and is available in markets as suspension." | 3.79 | Optimization and evaluation of desloratadine oral strip: an innovation in paediatric medication. ( Kaur, M; Singh, H; Verma, H, 2013) |
| " This study assessed the effect of long-lasting treatment with montelukast alone or in combination with antihistamines on wheal and flare in skin pricks tests (SPT) in patients sensitized to perennial allergens." | 2.79 | Wheal and flare reactions in skin prick tests of patients treated with montelukast alone or in combination with antihistamines. ( Barylski, M; Ciebiada, M; Ciebiada, MG, 2014) |
| "The treatment with desloratadine normalized the superoxide dismutase and catalase activity as well as the malondialdehyde formation." | 2.75 | Influence of desloratadine on selected oxidative stress markers in patients between 3 and 10 years of age with allergic perennial rhinitis. ( Bieszczad-Bedrejczuk, E; Rachel, M; Sadowska-Woda, I, 2010) |
| "Desloratadine has no effect in attenuating the broncho-constriction caused by exercise in patients with allergic rhinitis and exercise induced broncho-constriction." | 2.74 | Effect of desloratadine on patients with allergic rhinitis and exercise-induced bronchoconstriction: a placebo controlled study. ( Maharaj, B; Manjra, AI; Nel, H, 2009) |
| "Desloratadine was effective and safe." | 2.74 | Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study. ( Bachert, C; Bindslev Jensen, C; Bousquet, J; Canonica, GW; Fokkens, WJ; Keith, P; Lorber, R; Mullol, J; Ring, J; Van Cauwenberge, P; Zuberbier, T, 2009) |
| "Desloratadine was significantly more effective than placebo in reducing morning and evening reflective TSSs for each week and during weeks 1 through 4 (P = ." | 2.72 | Desloratadine therapy for symptoms associated with perennial allergic rhinitis. ( Gates, D; Hébert, J; Kim, K; Lumry, W; Lutsky, B; Sussman, G, 2006) |
| "In the study involving subjects aged 2 years-5 years (n = 111), the incidence of adverse events was 7/55 for the group treated with desloratadine and 6/56 for placebo." | 2.71 | Safety of desloratadine syrup in children. ( Bloom, M; Herron, J; Staudinger, H, 2004) |
| "Nasal obstruction is the main symptom in patients with perennial allergic rhinitis." | 2.71 | Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. ( Allen, M; Barberi, S; Ciprandi, G; Cirillo, I; Civardi, E; Marseglia, GL; Vizzaccaro, A, 2005) |
| "9 ln (mmol/L) x mm2 at each time (before dosing and 2, 4, 24 hours after dosing) respectively." | 2.71 | [Comparative activity of antihistamines on area under dose-response curve from histamine-induced wheal and flare responses in human skin]. ( Wang, RQ; Zhang, HY, 2004) |
| "We hypothesized that desloratadine, a new, nonsedating selective H1-antihistamine, would be efficacious and safe in the treatment of perennial allergic rhinitis." | 2.71 | Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. ( Finn, A; Prenner, BM; Simons, FE, 2003) |
| "Mizolastine treatment resulted in a significantly greater decrease in patient-rated total nasal score than placebo after 2 weeks (D14; -42%, P < 0." | 2.70 | Mizolastine provides effective symptom relief in patients suffering from perennial allergic rhinitis: a double-blind, placebo-controlled study versus loratadine. ( Antosova, E; Bachert, C; Frèche, C; Goos, M; Gracia, FD; Hide, D; Horak, F; Horvath, A; Leynadier, F; Soussen, PB; Verrecchia, M, 2002) |
| "Loratadine was significantly better than placebo for physician ratings of total symptom severity averaged over the two days and for the physician and subject ratings of the nasal cluster on day 3." | 2.69 | Brompheniramine, loratadine, and placebo in allergic rhinitis: a placebo-controlled comparative clinical trial. ( Brandon, ML; Druce, HM; Furey, SA; Galant, S; Lockhart, EA; Mure, P; Prenner, BM; Thoden, WR; Weinstein, S; Xie, T; Ziering, R, 1998) |
| " 5 mg loratadine plus 120 mg pseudoephedrine was safe and effective in relieving the symptoms of allergic rhinitis." | 2.69 | [Evaluation of the efficiency and safety of the loratadine with pseudoephedrine combination drug in treatment of seasonal allergic rhinitis]. ( Lipiec, A; Rapiejko, P; Zawisza, E, 1998) |
| "Treatment with loratadine attenuated early antigen-induced nasal obstruction, rhinorrhea, and itching." | 2.69 | In vivo and ex vivo inhibitory effects of loratadine on histamine release in patients with allergic rhinitis. ( Cottini, M; Danzig, M; Miadonna, A; Milazzo, N; Tedeschi, A; Tosi, D, 1998) |
| " Twenty-four hours after intake, the dose-response curve of nasal obstruction to histamine was significantly lower after treatment with cetirizine compared with placebo (P < 0." | 2.69 | Nasal effect of cetirizine and loratadine at 24 hours in patients with allergic rhinitis. ( Benabdesselam, O; Frossard, N; Glasser, N; Lacronique, J; Melac, M; Pauli, G, 1998) |
| "Cetirizine was more effective than loratadine in inhibiting the wheal response to histamine challenge and afforded greater reductions in most individual symptoms assessed daily by the parent." | 2.69 | Double-blind comparison of cetirizine and loratadine in children ages 2 to 6 years with perennial allergic rhinitis. ( Del Rio-Navarro, B; Gazca-Aguilar, A; Sienra-Monge, JJ, 1999) |
| " Somnolence scores were similar for both groups at baseline and at the time of dosing (8:00 AM)." | 2.69 | Loratadine versus cetirizine: assessment of somnolence and motivation during the workday. ( Gates, D; Greiding, L; Heithoff, K; Ramon, F; Salmun, LM; Scharf, M, 2000) |
| "Mizolastine is a new, non-sedating antihistamine providing satisfactory symptomatic relief in seasonal allergic rhinitis." | 2.68 | Comparison of mizolastine with loratadine in the treatment of perennial allergic rhinitis. ( Bellioni, P; Carraro, A; Catalano, B; Cervellera, G; Filiaci, F; Mira, E, 1996) |
| "Sinusitis was diagnosed by symptoms and confirmed by rhinoscopy and sinus radiograph." | 2.68 | Adjunct effect of loratadine in the treatment of acute sinusitis in patients with allergic rhinitis. ( Alabert, JP; Bousquet, J; Braun, JJ; Cougnard, J; Czarlewski, W; Michel, FB; Quiniou, M; Rat, C, 1997) |
| "Loratadine was administered in a single daily dose of 5 mg (2." | 2.67 | [Loratadine and dexchlorpheniramine in the treatment of perennial allergic rhinitis in pediatric patients]. ( Longo, G; Marchesi, E; Poli, F; Ventura, A, 1990) |
| "Loratadine was safe and well tolerated and was significantly less sedative than clemastine; loratadine may therefore possess an advantage in clinical use in the treatment of perennial allergic rhinitis." | 2.67 | A multicentre study of loratadine, clemastine and placebo in patients with perennial allergic rhinitis. ( Etholm, B; Frølund, L; Irander, K; Johannessen, TA; Odkvist, L; Ohlander, B; Weeke, B, 1990) |
| " Desloratadine is highly selective for histamine H₁-receptors, does not cross the blood-brain barrier (BBB), and has minimal adverse events (very low sedation rate), with a better safety and tolerability than first-generation antihistamines." | 2.49 | Safety evaluation of desloratadine in allergic rhinitis. ( González-Núñez, V; Mullol, J; Valero, A, 2013) |
| " Mean reductions in nasal congestion scores were comparable between the once- and twice-daily dosing regimens of the combination drug." | 2.45 | Desloratadine and pseudoephedrine combination therapy as a comprehensive treatment for allergic rhinitis and nasal congestion. ( Anolik, R, 2009) |
| "Desloratadine has been approved by the European Medicines Evaluation Agency for the treatment of intermittent and persistent AR, as defined by the ARIA classification." | 2.44 | Desloratadine treatment for intermittent and persistent allergic rhinitis: a review. ( Bachert, C; van Cauwenberge, P, 2007) |
| " No major cytochrome P450 inhibition has been reported with desloratadine, fexofenadine and levocetirizine, and the bioavailability of desloratadine is minimally affected by drugs interfering with transporter molecules." | 2.44 | Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. ( Devillier, P; Faisy, C; Roche, N, 2008) |
| " Although first-generation antihistamines can cause sedation and cognitive impairment, second-generation antihistamines are relatively non-sedating and free of such adverse events owing to their comparative inability to penetrate the blood-brain barrier." | 2.43 | The safety and efficacy of desloratadine for the management of allergic disease. ( Berger, WE, 2005) |
| "Desloratadine is a once-daily, non-sedating, non-impairing, selective histamine H1-receptor antagonist." | 2.43 | Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. ( DuBuske, LM, 2005) |
| "Desloratadine was used as a probe to further elucidate the mechanisms involved during an allergic response." | 2.42 | Anti-inflammatory properties of desloratadine. ( Agrawal, DK, 2004) |
| "Triamcinolone is a commonly used synthetic corticosteroid that has recently been tested in a large clinical trial for chronic obstructive pulmonary disease and shown to have some benefits." | 2.41 | Triamcinolone: new and old indications. ( Doggrell, SA, 2001) |
| "Loratadine is a long acting antihistamine which has a high selectivity for peripheral histamine H1-receptors and lacks the central nervous system depressant effects often associated with some of the older antihistamines." | 2.38 | Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy. ( Clissold, SP; Goa, KL; Sorkin, EM, 1989) |
| "Nearly 100 cases of atopic myelitis have been reported in Japan." | 1.37 | Atopic myelitis in a European woman residing in Japan. ( Bodini, B; Ciccarelli, O; Isaacs, JD; Scadding, GK; Thompson, AJ, 2011) |
| " Alternative dosage forms such as liquids or oral disintegrating tablets are available for most agents, allowing ease of administration to most young children and infants; however, limited data are available regarding use in infants for most agents, except desloratadine, cetirizine and montelukast." | 1.35 | Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. ( Moeller, ML; Nahata, MC; Phan, H, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (3.06) | 18.7374 |
| 1990's | 20 (20.41) | 18.2507 |
| 2000's | 59 (60.20) | 29.6817 |
| 2010's | 16 (16.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, J | 1 |
| Yan, X | 1 |
| Gai, J | 1 |
| Han, J | 1 |
| Zhang, H | 1 |
| Luo, H | 2 |
| Huang, S | 1 |
| Wang, J | 2 |
| González-Núñez, V | 1 |
| Valero, A | 1 |
| Mullol, J | 3 |
| Cingi, C | 1 |
| Oghan, F | 1 |
| Eskiizmir, G | 1 |
| Yaz, A | 1 |
| Ural, A | 1 |
| Erdogmus, N | 1 |
| Singh, H | 1 |
| Kaur, M | 1 |
| Verma, H | 1 |
| Ciebiada, MG | 2 |
| Barylski, M | 1 |
| Ciebiada, M | 3 |
| Lu, Y | 1 |
| Yin, M | 1 |
| Cheng, L | 2 |
| Wang, R | 1 |
| Zhang, C | 1 |
| Durham, SR | 1 |
| Creticos, PS | 1 |
| Nelson, HS | 1 |
| Li, Z | 1 |
| Kaur, A | 1 |
| Meltzer, EO | 1 |
| Nolte, H | 1 |
| Kmiecik, T | 1 |
| DuBuske, LM | 3 |
| Gorski, P | 2 |
| Manjra, AI | 1 |
| Nel, H | 1 |
| Maharaj, B | 1 |
| Tao, Z | 1 |
| Yan, N | 1 |
| Liang, J | 1 |
| Wang, P | 1 |
| Anolik, R | 1 |
| dos Santos, RV | 1 |
| Magerl, M | 1 |
| Mlynek, A | 1 |
| Lima, HC | 1 |
| Bousquet, J | 3 |
| Bachert, C | 5 |
| Canonica, GW | 3 |
| Van Cauwenberge, P | 5 |
| Bindslev Jensen, C | 1 |
| Fokkens, WJ | 2 |
| Ring, J | 2 |
| Keith, P | 2 |
| Lorber, R | 2 |
| Zuberbier, T | 2 |
| Holmberg, K | 1 |
| Tonnel, AB | 1 |
| Dreyfus, I | 1 |
| Olsson, P | 1 |
| Cougnard, J | 2 |
| Mesbah, K | 1 |
| Devillier, P | 2 |
| Phan, H | 1 |
| Moeller, ML | 1 |
| Nahata, MC | 1 |
| Sadowska-Woda, I | 1 |
| Bieszczad-Bedrejczuk, E | 1 |
| Rachel, M | 1 |
| Jensen, CB | 1 |
| Gopalan, G | 1 |
| Isaacs, JD | 1 |
| Bodini, B | 1 |
| Ciccarelli, O | 1 |
| Scadding, GK | 1 |
| Thompson, AJ | 1 |
| Sun, GM | 1 |
| Yang, XD | 1 |
| Xu, XG | 1 |
| Li, PH | 1 |
| Liu, W | 1 |
| Pan, LJ | 1 |
| Yan, ZQ | 1 |
| Zhang, RX | 1 |
| Yu, SQ | 1 |
| Wen, W | 1 |
| Hong, JK | 1 |
| Zhang, J | 1 |
| Shao, XL | 1 |
| Gao, SH | 1 |
| Mösges, R | 1 |
| König, V | 1 |
| Köberlein, J | 1 |
| Gadzhimirzaev, GA | 1 |
| Mikhrailova, ZT | 1 |
| Akhmedov, IG | 1 |
| Muradova, GR | 1 |
| Carter, NJ | 1 |
| Frèche, C | 1 |
| Leynadier, F | 1 |
| Horak, F | 3 |
| Hide, D | 1 |
| Gracia, FD | 1 |
| Goos, M | 1 |
| Horvath, A | 1 |
| Antosova, E | 1 |
| Verrecchia, M | 1 |
| Soussen, PB | 1 |
| Sabbah, A | 1 |
| Simons, FE | 4 |
| Prenner, BM | 2 |
| Finn, A | 1 |
| He, WQ | 1 |
| Zheng, JP | 1 |
| Ran, PX | 1 |
| Liu, HZ | 1 |
| Lin, H | 1 |
| Cai, DM | 1 |
| Xu, JM | 1 |
| Zhong, NS | 1 |
| Haberal, I | 1 |
| Corey, JP | 1 |
| Berberabe, T | 1 |
| Lee, LM | 1 |
| Gendeh, BS | 1 |
| See, S | 1 |
| Bonanni, L | 1 |
| Parmiani, S | 1 |
| Sturbini, S | 1 |
| Lee, DK | 2 |
| Gardiner, M | 1 |
| Haggart, K | 1 |
| Fujihara, S | 1 |
| Lipworth, BJ | 1 |
| Magnan, A | 1 |
| Stübner, P | 1 |
| Zieglmayer, R | 1 |
| Agrawal, DK | 1 |
| Currie, GP | 1 |
| Wang, RQ | 1 |
| Zhang, HY | 1 |
| Bloom, M | 1 |
| Staudinger, H | 1 |
| Herron, J | 1 |
| Bhatia, S | 1 |
| Baroody, FM | 2 |
| deTineo, M | 1 |
| Naclerio, RM | 2 |
| Li, X | 1 |
| Zhao, Y | 2 |
| Van Hasselt, CA | 3 |
| Woo, K | 2 |
| Wong, Y | 2 |
| Leung, P | 2 |
| Sullivan, PW | 1 |
| Nair, KV | 1 |
| Patel, BV | 1 |
| Passalacqua, G | 1 |
| Ciprandi, G | 1 |
| Cirillo, I | 1 |
| Vizzaccaro, A | 1 |
| Civardi, E | 1 |
| Barberi, S | 1 |
| Allen, M | 1 |
| Marseglia, GL | 1 |
| Berger, WE | 1 |
| Montaño Velázquez, BB | 1 |
| Jáuregui-Renaud, K | 1 |
| Bañuelos Arias, Adel C | 1 |
| Ayala, JC | 1 |
| Martínez, MD | 1 |
| Campillo Navarrete, R | 1 |
| Rosalia, IS | 1 |
| Salazar, Mdel R | 1 |
| Serrano, HA | 1 |
| Mondragón, AO | 1 |
| Perez, RL | 1 |
| Jiang, RS | 1 |
| Kim, K | 1 |
| Sussman, G | 2 |
| Hébert, J | 2 |
| Lumry, W | 1 |
| Lutsky, B | 1 |
| Gates, D | 2 |
| Górska-Ciebiada, M | 1 |
| Lehman, JM | 1 |
| Blaiss, MS | 1 |
| Hung, CH | 1 |
| Hua, YM | 1 |
| Hsu, WT | 1 |
| Lai, YS | 1 |
| Yang, KD | 1 |
| Jong, YJ | 1 |
| Chu, YT | 1 |
| Lam, HC | 1 |
| Tong, MC | 1 |
| Liu, Y | 1 |
| Roche, N | 1 |
| Faisy, C | 1 |
| Goebel, MU | 1 |
| Meykadeh, N | 1 |
| Kou, W | 1 |
| Schedlowski, M | 1 |
| Hengge, UR | 1 |
| Carlsen, KH | 1 |
| Kramer, J | 1 |
| Fagertun, HE | 1 |
| Larsen, S | 1 |
| Lim, MC | 1 |
| Proud, D | 1 |
| Kagey-Sobotka, A | 1 |
| Lichtenstein, LM | 1 |
| Drouin, M | 1 |
| Yang, WH | 1 |
| Bertrand, B | 1 |
| Clement, P | 1 |
| Dalby, K | 1 |
| Darnell, R | 1 |
| Ernst, TM | 1 |
| Karlsson, G | 1 |
| Luciuk, G | 1 |
| Mazza, J | 1 |
| Roovers, M | 1 |
| Ruoppi, P | 1 |
| Seppey, M | 1 |
| Stern, M | 1 |
| Suonpää, J | 1 |
| Tan, KY | 1 |
| Tse, K | 1 |
| Widjaja, P | 1 |
| Jensen, P | 1 |
| Nolop, K | 1 |
| Lutsky, BN | 1 |
| Bellioni, P | 1 |
| Catalano, B | 1 |
| Cervellera, G | 1 |
| Filiaci, F | 1 |
| Mira, E | 1 |
| Carraro, A | 1 |
| Braun, JJ | 1 |
| Alabert, JP | 1 |
| Michel, FB | 1 |
| Quiniou, M | 1 |
| Rat, C | 1 |
| Czarlewski, W | 1 |
| Dumonceaux, GA | 1 |
| Lamberski, N | 1 |
| Clutter, D | 1 |
| Nagy, SM | 1 |
| Burek, K | 1 |
| Phillips, LG | 1 |
| Day, JH | 1 |
| Briscoe, MP | 1 |
| Clark, RH | 1 |
| Ellis, AK | 1 |
| Gervais, P | 1 |
| Pospelova, RA | 1 |
| Akimova, LG | 1 |
| Kolganova, NA | 1 |
| Zlatinskaia, GR | 1 |
| Druce, HM | 1 |
| Thoden, WR | 1 |
| Mure, P | 1 |
| Furey, SA | 1 |
| Lockhart, EA | 1 |
| Xie, T | 1 |
| Galant, S | 1 |
| Weinstein, S | 1 |
| Ziering, R | 1 |
| Brandon, ML | 1 |
| Crawford, WW | 1 |
| Klaustermeyer, WB | 1 |
| Lee, PH | 1 |
| Placik, IM | 1 |
| Zawisza, E | 1 |
| Lipiec, A | 1 |
| Rapiejko, P | 1 |
| Aelony, Y | 1 |
| Miadonna, A | 1 |
| Cottini, M | 1 |
| Milazzo, N | 1 |
| Tosi, D | 1 |
| Danzig, M | 1 |
| Tedeschi, A | 1 |
| Ricard, N | 1 |
| Kind, P | 1 |
| Christian, S | 1 |
| Jensen, M | 1 |
| Stewart, J | 1 |
| Frossard, N | 1 |
| Benabdesselam, O | 1 |
| Melac, M | 1 |
| Glasser, N | 1 |
| Lacronique, J | 1 |
| Pauli, G | 1 |
| Sienra-Monge, JJ | 1 |
| Gazca-Aguilar, A | 1 |
| Del Rio-Navarro, B | 1 |
| Salmun, LM | 1 |
| Scharf, M | 1 |
| Greiding, L | 1 |
| Ramon, F | 1 |
| Heithoff, K | 1 |
| Lee, J | 1 |
| Cummins, G | 2 |
| Okamoto, L | 1 |
| Branco-Ferreira, M | 1 |
| dos Santos, MC | 1 |
| Palma-Carlos, ML | 2 |
| Palma-Carlos, AG | 2 |
| Doggrell, SA | 1 |
| Liao, E | 1 |
| Leahy, M | 1 |
| Kósa, L | 1 |
| Kovács, N | 1 |
| Halász, A | 1 |
| Zsigmond, G | 1 |
| Nwawolo, CC | 1 |
| Olusesi, AD | 1 |
| Ferreira, MB | 1 |
| Santos, MC | 1 |
| Pregal, AL | 1 |
| Alonso, E | 1 |
| Santos, AS | 1 |
| Yang, YH | 1 |
| Lin, YT | 1 |
| Lu, MY | 1 |
| Tsai, MJ | 1 |
| Chiang, BL | 1 |
| Lukowski, JL | 1 |
| Becker, AB | 1 |
| Simons, KJ | 1 |
| Longo, G | 1 |
| Poli, F | 1 |
| Ventura, A | 1 |
| Marchesi, E | 1 |
| Frølund, L | 1 |
| Etholm, B | 1 |
| Irander, K | 1 |
| Johannessen, TA | 1 |
| Odkvist, L | 1 |
| Ohlander, B | 1 |
| Weeke, B | 1 |
| Clissold, SP | 1 |
| Sorkin, EM | 1 |
| Goa, KL | 1 |
| Bruttmann, G | 1 |
| Charpin, D | 1 |
| Germouty, J | 1 |
| Kunkel, G | 1 |
| Wittmann, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet the Criteria for Intermittent Allergic Rhinitis (IAR)[NCT00406783] | Phase 3 | 547 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age[NCT04957927] | Phase 4 | 60 participants (Anticipated) | Interventional | 2020-12-12 | Recruiting | ||
| Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet the Criteria for Persistent Allergic Rhinitis (PER)[NCT00405964] | Phase 3 | 716 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Quality of Life in Patients With Allergic Rhinitis: a Clinical Trial Comparing the Use of Bilastine Versus Loratadine[NCT02513290] | Phase 4 | 73 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| Nasal Ocular Reflexes Contribute to Eye Symptoms in Patients With Allergic Rhinitis[NCT00117832] | 20 participants | Interventional | 2005-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The RQLQ-S questionnaire consists of 28 questions grouped into 7 domains. Each question is scored on a scale of 0 (not troubled with symptoms) to 6 (extremely troubled with symptoms). The total RQLQ-S score is the average score of the 28 questions which consisted of a total of 7 domains. (NCT00406783)
Timeframe: 15 days
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| 5-mg Desloratadine Tablet | -1.1 |
| Placebo Tablet | -0.73 |
The RQLQ-S questionnaire consists of 28 questions grouped into 7 domains. Each question is scored on a scale of 0 (not troubled with symptoms) to 6 (extremely troubled with symptoms). The total RQLQ-S score is the average score of the 28 questions which consisted of a total of 7 domains. (NCT00406783)
Timeframe: Baseline
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| 5-mg Desloratadine Tablet | 2.96 |
| Placebo Tablet | 2.80 |
AM/PM is the average of separate morning (AM) and evening (PM) evaluations. T5SS = the sum of the individual scores for nasal congestion/stuffiness, sneezing, rhinorrhea/nasal discharge, nasal pruritis, and ocular pruritis. Each individual symptom/sign was scored from 0 (none) to 3 (severe). (NCT00406783)
Timeframe: 15 days
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| 5-mg Desloratadine Tablet | -3.01 |
| Placebo Tablet | -2.13 |
AM/PM is the average of separate morning (AM) and evening (PM) evaluations. T5SS = the sum of the individual scores for nasal congestion/stuffiness, sneezing, rhinorrhea/nasal discharge, nasal pruritis, and ocular pruritis. Each individual symptom/sign was scored from 0 (none) to 3 (severe). (NCT00406783)
Timeframe: Baseline
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| 5-mg Desloratadine Tablet | 8.5 |
| Placebo Tablet | 8.33 |
AM/PM PRIOR (the participant's status over previous 12 hours) T5SS from the participant's daily diary averaged over treatment Days 1 to 85. AM/PM is the average of separate AM and PM evaluations. Scores were defined for T5SS as 0: no symptoms to 15: all severe symptoms. A two-way analysis of variance (ANOVA) model with treatment and site effects was used to examine the treatment difference. (NCT00405964)
Timeframe: Baseline and Days 1-85
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Days 1-85 | |
| 5-mg Desloratadine Tablet | 9.63 | -4.50 |
| Placebo Tablet | 9.55 | -3.61 |
AM/PM PRIOR (the participant's status over previous 12 hours) T5SS from the participant's daily diary averaged over treatment Days 1 to 29. AM/PM is the average of separate morning (AM) and evening (PM) evaluations. Scores were defined for T5SS as 0: no symptoms to 15: all severe symptoms. A two-way analysis of variance (ANOVA) model with treatment and site effects was used to examine the treatment difference. (NCT00405964)
Timeframe: Baseline and Days 1-29
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Days 1-29 | |
| 5-mg Desloratadine Tablet | 9.63 | -3.76 |
| Placebo Tablet | 9.55 | -2.87 |
The RQLQ-S was only completed for participants above 18 years of age. The RQLQ-S was not available for participants 12 to 17 years of age. This questionnaire asked questions pertaining to daily activities, sleep, non-nose eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotions. The scale went from 0 (not troubled) to 6 (extremely troubled). A two-way analysis of variance (ANOVA) model with treatment and site effects was used to examine the treatment difference. (NCT00405964)
Timeframe: Baseline and Day 29
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Day 29 | |
| 5-mg Desloratadine Tablet | 3.30 | -1.35 |
| Placebo Tablet | 3.15 | -0.95 |
21 reviews available for loratadine and Rhinitis, Allergic, Perennial
| Article | Year |
|---|---|
Safety evaluation of desloratadine in allergic rhinitis.
Topics: Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Rhinitis, Allergic; Rhinitis, Allergic, | 2013 |
[Meta-analysis of leukotriene receptor antagonist montelukast in the treatment of allergic rhinitis].
Topics: Acetates; Cyclopropanes; Drug Therapy, Combination; Humans; Leukotriene Antagonists; Loratadine; Nos | 2014 |
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses.
Topics: Ambrosia; Anti-Allergic Agents; Humans; Loratadine; Mometasone Furoate; Phleum; Rhinitis, Allergic, | 2016 |
Desloratadine and pseudoephedrine combination therapy as a comprehensive treatment for allergic rhinitis and nasal congestion.
Topics: Clinical Trials as Topic; Drug Combinations; Histamine H1 Antagonists, Non-Sedating; Humans; Loratad | 2009 |
The effectiveness of levocetirizine in comparison with loratadine in treatment of allergic rhinitis--a meta-analysis.
Topics: Anti-Allergic Agents; Cetirizine; Humans; Loratadine; Rhinitis, Allergic, Perennial; Rhinitis, Aller | 2011 |
Bilastine: in allergic rhinitis and urticaria.
Topics: Area Under Curve; Benzimidazoles; Cetirizine; Histamine H1 Antagonists, Non-Sedating; Humans; Lorata | 2012 |
Therapeutic points of intervention and clinical implications: role of desloratadine.
Topics: Asthma; Clinical Trials as Topic; Drug Administration Schedule; Histamine H1 Antagonists; Humans; Lo | 2002 |
Advances in allergy management.
Topics: Histamine H1 Antagonists; Humans; Inflammation Mediators; Loratadine; Nasal Obstruction; Quality of | 2002 |
[The place of new antihistamines in allergy management. Apropos of desloratadine].
Topics: Anti-Allergic Agents; Double-Blind Method; Half-Life; Histamine H1 Antagonists; Histamine Release; H | 2002 |
The role of leukotrienes in nasal allergy.
Topics: Acetates; Anti-Allergic Agents; Collagen; Cyclopropanes; Eosinophils; Goblet Cells; Humans; Immunogl | 2003 |
Desloratadine for allergic rhinitis.
Topics: Administration, Oral; Adolescent; Adult; Drug Administration Schedule; Drug Costs; Histamine H1 Anta | 2003 |
Anti-inflammatory properties of desloratadine.
Topics: Cell Adhesion; Cytokines; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Models, Immuno | 2004 |
A review of the evidence from comparative studies of levocetirizine and desloratadine for the symptoms of allergic rhinitis.
Topics: Cetirizine; Histamine Antagonists; Humans; Loratadine; Nose; Piperazines; Quality of Life; Randomize | 2005 |
Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders.
Topics: Adult; Aged; Animals; Anti-Inflammatory Agents; Asthma; Child; Child, Preschool; Chronic Disease; Cl | 2005 |
The safety and efficacy of desloratadine for the management of allergic disease.
Topics: Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Product Surveillance, Postmarketing; Ran | 2005 |
Selecting the optimal oral antihistamine for patients with allergic rhinitis.
Topics: Administration, Oral; Cardiovascular System; Central Nervous System; Cetirizine; Drug Interactions; | 2006 |
Desloratadine treatment for intermittent and persistent allergic rhinitis: a review.
Topics: Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Practice Guidelines as Topic; Quality of | 2007 |
Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.
Topics: Cetirizine; Drug Interactions; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Rhinitis, | 2008 |
Triamcinolone: new and old indications.
Topics: Administration, Intranasal; Adult; Aerosols; Androstadienes; Anti-Inflammatory Agents; Arthritis, Rh | 2001 |
Recent advances in H1-receptor antagonist treatment.
Topics: Astemizole; Benzhydryl Compounds; Benzimidazoles; Cetirizine; Cyproheptadine; Histamine H1 Antagonis | 1990 |
Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
Topics: Animals; Common Cold; Cyproheptadine; Female; Humans; Loratadine; Male; Rhinitis, Allergic, Perennia | 1989 |
52 trials available for loratadine and Rhinitis, Allergic, Perennial
| Article | Year |
|---|---|
Efficacy of Bimin decoction for patients with perennial allergic rhinitis: an open-label non-inferiority randomized controlled trial.
Topics: Adult; Anti-Allergic Agents; Drugs, Chinese Herbal; Female; Fluticasone; Humans; Loratadine; Male; M | 2019 |
Desloratadine-montelukast combination improves quality of life and decreases nasal obstruction in patients with perennial allergic rhinitis.
Topics: Acetates; Adult; Cyclopropanes; Drug Combinations; Female; Humans; Leukotriene Antagonists; Loratadi | 2013 |
Wheal and flare reactions in skin prick tests of patients treated with montelukast alone or in combination with antihistamines.
Topics: Acetates; Adolescent; Adult; Aged; Antigens; Antigens, Dermatophagoides; Cetirizine; Cross-Over Stud | 2014 |
[Clinical evaluation of Montelukast plus Budesonide nasal spray and Desloratadine citrate disodium in treating moderate and severe persistent allergic rhinitis].
Topics: Acetates; Budesonide; Cyclopropanes; Humans; Loratadine; Nasal Sprays; Quinolines; Rhinitis, Allergi | 2015 |
Quality of life in patients with persistent allergic rhinitis treated with montelukast alone or in combination with levocetirizine or desloratadine.
Topics: Acetates; Adolescent; Adult; Aged; Cetirizine; Chronic Disease; Cross-Over Studies; Cyclopropanes; D | 2008 |
Effect of desloratadine on patients with allergic rhinitis and exercise-induced bronchoconstriction: a placebo controlled study.
Topics: Adolescent; Area Under Curve; Asthma, Exercise-Induced; Child; Cross-Over Studies; Double-Blind Meth | 2009 |
[Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis].
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Female; Histamine H1 Antagonists, Non-Sedating; Human | 2009 |
Suppression of histamine- and allergen-induced skin reactions: comparison of first- and second-generation antihistamines.
Topics: Adult; Allergens; Animals; Dermatophagoides pteronyssinus; Dibenzazepines; Double-Blind Method; Fema | 2009 |
Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study.
Topics: Adult; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Male | 2009 |
Desloratadine relieves nasal congestion and improves quality-of-life in persistent allergic rhinitis.
Topics: Adult; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Male | 2009 |
Influence of desloratadine on selected oxidative stress markers in patients between 3 and 10 years of age with allergic perennial rhinitis.
Topics: Biomarkers; Case-Control Studies; Catalase; Child; Child, Preschool; Female; Humans; Hydrogen Peroxi | 2010 |
Efficacy of desloratadine in persistent allergic rhinitis - a GA²LEN study.
Topics: Adult; Disease Progression; Female; Follow-Up Studies; Histamine H1 Antagonists, Non-Sedating; Human | 2010 |
Mizolastine provides effective symptom relief in patients suffering from perennial allergic rhinitis: a double-blind, placebo-controlled study versus loratadine.
Topics: Adolescent; Adult; Anti-Allergic Agents; Benzimidazoles; Double-Blind Method; Female; Histamine H1 A | 2002 |
Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis.
Topics: Adolescent; Adult; Aged; Child; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; | 2003 |
[Effects of H1 blocker and inhaled corticosteroids on asthmatic patients with allergic rhinitis].
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Asthmatic Agents; Asthma; Beclomethasone; Child; | 2003 |
Pre and post treatment mucociliary function in allergic rhinitis in three different treatment modalities.
Topics: Administration, Intranasal; Administration, Oral; Anti-Inflammatory Agents; Beclomethasone; Drug The | 2003 |
Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Anti-Allergic Agents; Cetirizine; Cross-Ove | 2004 |
A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit - the Vienna Challenge Chamber (VCC).
Topics: Cetirizine; Cross-Over Studies; Double-Blind Method; Environmental Exposure; Female; Histamine H1 An | 2004 |
[Comparative activity of antihistamines on area under dose-response curve from histamine-induced wheal and flare responses in human skin].
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Area Under Curve; Benzimidazoles; Double-Blind Method | 2004 |
Safety of desloratadine syrup in children.
Topics: Acute Disease; Administration, Oral; Child; Child, Preschool; Double-Blind Method; Electrocardiograp | 2004 |
Increased nasal airflow with budesonide compared with desloratadine during the allergy season.
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Budesonide; Cross-Sectional Stu | 2005 |
Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study.
Topics: Adolescent; Adult; Cetirizine; Double-Blind Method; Eosinophils; Female; Histamine H1 Antagonists, N | 2005 |
Vitamin E effects on nasal symptoms and serum specific IgE levels in patients with perennial allergic rhinitis.
Topics: Adolescent; Adult; Allergens; Antioxidants; Child; Dietary Supplements; Double-Blind Method; Ephedri | 2006 |
Efficacy of a leukotriene receptor antagonist in the treatment of perennial allergic rhinitis.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Ephedrine; Female; Humans; Indoles; Leukotriene Antag | 2006 |
Desloratadine therapy for symptoms associated with perennial allergic rhinitis.
Topics: Adolescent; Adult; Aged; Child; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; | 2006 |
Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis.
Topics: Acetates; Adolescent; Adult; Aged; Anti-Asthmatic Agents; Cetirizine; Cross-Over Studies; Cyclopropa | 2006 |
Montelukast decreased exhaled nitric oxide in children with perennial allergic rhinitis.
Topics: Acetates; Administration, Intranasal; Administration, Oral; Adolescent; Anti-Allergic Agents; Anti-A | 2007 |
Rhinitis symptoms and quality of life in patients with chronic perennial rhinitis treated with desloratadine.
Topics: Adult; Chronic Disease; Endoscopy; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadin | 2007 |
[Cardiac safety evaluation of loratadine in the treatment of allergic rhinitis in elderly patients].
Topics: Aged; Aged, 80 and over; Drug Evaluation; Electrocardiography; Female; Heart; Histamine H1 Antagonis | 2007 |
Behavioral conditioning of antihistamine effects in patients with allergic rhinitis.
Topics: Adult; Animals; Association Learning; Basophils; Conditioning, Classical; Female; Histamine H1 Antag | 2008 |
Loratadine and terfenadine in perennial allergic rhinitis. Treatment of nonresponders to the one drug with the other drug.
Topics: Adolescent; Adult; Aged; Child; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Immu | 1993 |
Effects of loratadine and terfenadine on the induced nasal allergic reaction.
Topics: Adult; Analysis of Variance; Cross-Over Studies; Double-Blind Method; Eosinophilia; Female; Histamin | 1996 |
Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients.
Topics: Administration, Intranasal; Adolescent; Adult; Anti-Inflammatory Agents; Beclomethasone; Child; Circ | 1996 |
Comparison of mizolastine with loratadine in the treatment of perennial allergic rhinitis.
Topics: Adult; Benzimidazoles; Double-Blind Method; Drug Administration Schedule; Female; Histamine H1 Antag | 1996 |
Adjunct effect of loratadine in the treatment of acute sinusitis in patients with allergic rhinitis.
Topics: Acute Disease; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Bacteria | 1997 |
Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis.
Topics: Adolescent; Adult; Anti-Allergic Agents; Astemizole; Cetirizine; Double-Blind Method; Environmental | 1997 |
Brompheniramine, loratadine, and placebo in allergic rhinitis: a placebo-controlled comparative clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Allergic Agents; Brompheniramine; Child; Double-Bli | 1998 |
Comparative efficacy of terfenadine, loratadine, and astemizole in perennial allergic rhinitis.
Topics: Adrenergic Agents; Allergens; Ambulatory Care; Analysis of Variance; Anti-Allergic Agents; Astemizol | 1998 |
[Evaluation of the efficiency and safety of the loratadine with pseudoephedrine combination drug in treatment of seasonal allergic rhinitis].
Topics: Adolescent; Adult; Anti-Allergic Agents; Drug Combinations; Ephedrine; Humans; Loratadine; Middle Ag | 1998 |
In vivo and ex vivo inhibitory effects of loratadine on histamine release in patients with allergic rhinitis.
Topics: Adult; Animals; Basophils; Cross-Over Studies; Double-Blind Method; Female; Histamine H1 Antagonists | 1998 |
Link between patient preferences and treatment outcomes in seasonal allergic rhinitis: an empiric investigation.
Topics: Adult; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Loratadine; Male; Patient Sati | 1999 |
Nasal effect of cetirizine and loratadine at 24 hours in patients with allergic rhinitis.
Topics: Adult; Cetirizine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female | 1998 |
Double-blind comparison of cetirizine and loratadine in children ages 2 to 6 years with perennial allergic rhinitis.
Topics: Cetirizine; Child, Preschool; Double-Blind Method; Eosinophils; Female; Histamine H1 Antagonists; Hu | 1999 |
Loratadine versus cetirizine: assessment of somnolence and motivation during the workday.
Topics: Adult; Anti-Allergic Agents; Cetirizine; Disorders of Excessive Somnolence; Double-Blind Method; Eff | 2000 |
Antihistamines and serum adhesion molecule levels.
Topics: Animals; Anti-Allergic Agents; Budesonide; Cromolyn Sodium; Drug Therapy, Combination; Histamine H1 | 2001 |
Controlled clinical study of the efficacy of loratadine in Nigerian patients with allergic rhinitis.
Topics: Adult; Anti-Allergic Agents; Chlorpheniramine; Female; Histamine H1 Antagonists; Humans; Loratadine; | 2001 |
Effect of specific immunotherapy versus loratadine on serum adhesion molecules.
Topics: Adolescent; Adult; Animals; Anti-Allergic Agents; Biomarkers; Cromolyn Sodium; Desensitization, Immu | 2001 |
A double-blind, placebo-controlled, and randomized study of loratadine (Clarityne) syrup for the treatment of allergic rhinitis in children aged 3 to 12 years.
Topics: Administration, Oral; Child; Child, Preschool; Double-Blind Method; Female; Histamine H1 Antagonists | 2001 |
Comparison of the effects of single doses of the new H1-receptor antagonists loratadine and terfenadine versus placebo in children.
Topics: Benzhydryl Compounds; Child; Cyproheptadine; Female; Histamine H1 Antagonists; Humans; Loratadine; M | 1991 |
[Loratadine and dexchlorpheniramine in the treatment of perennial allergic rhinitis in pediatric patients].
Topics: Age Factors; Child; Child, Preschool; Chlorpheniramine; Cyproheptadine; Female; Histamine Antagonist | 1990 |
A multicentre study of loratadine, clemastine and placebo in patients with perennial allergic rhinitis.
Topics: Adolescent; Adult; Aged; Clemastine; Cyproheptadine; Double-Blind Method; Female; Histamine Antagoni | 1990 |
Evaluation of the efficacy and safety of loratadine in perennial allergic rhinitis.
Topics: Adolescent; Adult; Benzhydryl Compounds; Child; Cyproheptadine; Double-Blind Method; Female; Histami | 1989 |
25 other studies available for loratadine and Rhinitis, Allergic, Perennial
| Article | Year |
|---|---|
Optimization and evaluation of desloratadine oral strip: an innovation in paediatric medication.
Topics: Chemistry, Pharmaceutical; Child; Drug Carriers; Humans; Loratadine; Materials Testing; Microscopy, | 2013 |
Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast.
Topics: Acetates; Administration, Oral; Adult; Anti-Allergic Agents; Anti-Asthmatic Agents; Astemizole; Ceti | 2009 |
Atopic myelitis in a European woman residing in Japan.
Topics: Adrenal Cortex Hormones; Adult; Brain Stem; Europe; Female; Gait Disorders, Neurologic; Histamine H1 | 2011 |
[Substance P and its receptors are involved in the effect of histamine H3 receptor agonist, IMETIT on nasal allergic symptoms in guinea pigs].
Topics: Animals; Female; Guinea Pigs; Histamine Agonists; Imidazoles; Loratadine; Male; Nasal Mucosa; Recept | 2010 |
[Effect of histamine H4 receptor and its antagonist on allergic rhinitis in rats].
Topics: Animals; Histamine Antagonists; Indoles; Loratadine; Male; Piperazines; Rats; Rats, Wistar; Receptor | 2010 |
[The role of disturbances of lipid metabolism in pathogenesis of allergic rhinitis].
Topics: Adolescent; Adult; Drug Administration Routes; Drug Therapy, Combination; Female; Histamine H1 Antag | 2011 |
[In seasonal and perennial rhinitis. Superiority to standard H1 blockers].
Topics: Anti-Allergic Agents; Butyrophenones; Cetirizine; Double-Blind Method; Histamine H1 Antagonists; His | 2003 |
[Antihistaminics. Side effects also after raising dosage at the placebo level].
Topics: Anti-Allergic Agents; Benzimidazoles; Butyrophenones; Cetirizine; Double-Blind Method; Histamine H1 | 2003 |
Coupon programs curb antihistamine utilization.
Topics: Anti-Allergic Agents; Blue Cross Blue Shield Insurance Plans; Drug Industry; Histamine H1 Antagonist | 2003 |
[Modern antihistaminics against allergic rhinitis. Better breathing without side effects].
Topics: Clinical Trials as Topic; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Nasal Obstruct | 2003 |
Glottis oedema due to loratadine.
Topics: Adult; Anti-Allergic Agents; Female; Follow-Up Studies; Humans; Laryngeal Edema; Loratadine; Prednis | 2004 |
[Respiratory allergies in the child and the adult].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Allergens; Anti-Allergic Ag | 2004 |
[Nasal obstruction on the decline. Antihistamine allows allergic patients to breathe].
Topics: Cholinergic Antagonists; Clinical Trials as Topic; Histamine H1 Antagonists, Non-Sedating; Humans; L | 2004 |
Modern histamine H1-receptor antagonists in the unified airway.
Topics: Cetirizine; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Nasal Obstruction; Nasal Pro | 2004 |
[Preliminary clinical study of fubiding in treatment of perennial allergic rhinitis].
Topics: Adolescent; Adult; Aged; Child; Female; Follow-Up Studies; Histamine H1 Antagonists, Non-Sedating; H | 2005 |
[The immunohistochemical observations of NOS in the nasal mucosa of allergic rhinitis animal model of guinea pigs].
Topics: Animals; Anti-Allergic Agents; Guinea Pigs; Immunohistochemistry; Isoenzymes; Loratadine; Nasal Muco | 2005 |
The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy.
Topics: Adult; Aged; Anti-Allergic Agents; California; Cost-Benefit Analysis; Drug Prescriptions; Drug Utili | 2005 |
[The effect of desloratadine on the TXB2 and leukotrienes levels in the nasal lavage fluid of allergic rhinitis animal model].
Topics: Animals; Female; Guinea Pigs; Histamine H1 Antagonists, Non-Sedating; Leukotrienes; Loratadine; Male | 2005 |
Treatment of bilateral nasal polyposis and chronic refractory inhalant allergic rhinitis in a chimpanzee (Pan troglodytes).
Topics: Animals; Anti-Allergic Agents; Desensitization, Immunologic; Endoscopy; Female; Fluorescence; Immuno | 1997 |
[Claritin in the combined therapy of bronchial asthma].
Topics: Anti-Asthmatic Agents; Asthma; Drug Evaluation; Histamine H1 Antagonists; Humans; Loratadine; Remiss | 1997 |
First-generation vs second-generation antihistamines.
Topics: Anti-Allergic Agents; Conflict of Interest; Diphenhydramine; Drug Industry; Histamine H1 Antagonists | 1998 |
A descriptive analysis of the use and cost of new-generation antihistamines in the treatment of allergic rhinitis: a retrospective database analysis.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Cetirizine; Child; Databases as Topic; Drug Utilizati | 2001 |
The costs of nonsedating antihistamine therapy for allergic rhinitis in managed care: an updated analysis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Cetirizine; Child; Cohort Studies; Drug Costs; Eco | 2001 |
[Effect of loratadine in children with allergic rhinitis].
Topics: Adolescent; Anti-Allergic Agents; Blood Proteins; Chemokine CCL5; Child; Child, Preschool; Eosinophi | 2001 |
Loratadine, a non-sedating H1-receptor antagonist (antihistamine)
Topics: Cyproheptadine; Histamine Antagonists; Histamine H1 Antagonists; Humans; Loratadine; Rhinitis, Aller | 1989 |